COVID-19 was first confirmed in Australia in late January 2020. Till now the total reported cases have been 7461 with 6896 recovered and 102 deaths. As per World Health Organisation, there have been 8,690,140 confirmed cases of COVID-19, globally, including 461,274 deaths reported to WHO.
Naturally, with no sign of abatement, the world has been scrambling to find a vaccine to treat the virus. Many drug development programmes are currently on in different parts of the world. This includes several major players.
The announcement by President Trump regarding availability of vaccine by the end of year was initially met with hope but later turned into doubt and skepticism indicating the desperation all over.
Vaccines normally take years of research and testing before reaching the clinics. They have to go through mainly pre clinical, safety, efficacy and approval phases before they can hit the market.
Although, most of the researches are moving forward with the sole aim to find new formulations, some are even trying old vaccines for a temporary relief. Many pharma companies which were in the final stages of starting human trials are already learnt to be advancing these dates.
As it becomes clearer that the vaccine availability may still be away by a few months, if not longer, there is developing another seemingly urgency. It is regarding anything which could be made available in the meantime to keep our economies running.
An intermediate could be a drug which could prevent people from getting really sick or dying but may not shield them from catching coronavirus.
Though the ultimate goal would be complete eradication of coronavirus, people may settle for a vaccine that could deliver albeit with some limitations. This could catalyse the return to pre pandemic life.
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.